


PHARMACEUTICAL 2018



Minerva Neurosciences Inc. Rank 104 of 342





PHARMACEUTICAL 2018



Minerva Neurosciences Inc. Rank 104 of 342

The relative strengths and weaknesses of Minerva Neurosciences Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Minerva Neurosciences Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 43% points. The greatest weakness of Minerva Neurosciences Inc. is the variable Other Liabilities, reducing the Economic Capital Ratio by 80% points.

The company's Economic Capital Ratio, given in the ranking table, is 165%, being 120% points above the market average of 46%.

Input Variable	Value in 1000 USD
Assets, Current	129,540
Cost of Goods Sold	0
Intangible Assets	49,069
Liabilities, Current	6,838
Liabilities, Non-Current	30
Other Assets	5,038
Other Compr. Net Income	0
Other Expenses	-9,376
Other Liabilities	45,233
Other Net Income	271
Other Revenues	0
Property and Equipment	51
Research and Development	30,256
Selling, General and Administrative Expense	10,914

Output Variable	Value in 1000 USD
Assets	183,699
Liabilities	52,101
Expenses	31,794
Revenues	0
Stockholders Equity	131,597
Net Income	-31,523
Comprehensive Net Income	-31,523
Economic Capital Ratio	165%

